Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Amazon invention a mere business solution and not patentable

Amazon Technologies, Inc. [2021] APO 7

by | Feb 16, 2021

Date: 16 February 2021
Forum: Australian Patent Office
Delegate: Kevin Restrick

Background

Under Australian law, business methods are not patent eligible because they are not considered to be a “manner of manufacture”. However, inventions that may resemble business methods, but that rely in both a technical intervention and a technical innovation to solve a problem may meet the requirements for patentability. Australian Patent Application 2018204629 (Application), in the name of Amazon Technologies, was the subject of a hearing after the Application and its parent application, failed to reach acceptance following six examination reports in which objections for manner of manufacture had been raised.

The claimed invention of the Application related to the field of computer resource virtualization and allowed various computing resources to be efficiently and securely shared by multiple customers. Prior to the hearing, the Examiner had maintained that the claimed invention did not involve any technical invention or ingenuity and that the technical aspects of the invention were achieved using generic computer functionalities.

Key Issues

In making his assessment, the Delegate carefully considered the substance of the invention based on the principles set out by the Delegate in Aristocrat Technologies Australia Pty Ltd.1

Specifically, the Delegate focused on identifying the problem to be solved, whether said problem was technical in nature, and whether the solution relied on a technical improvement to known computing technology.

The Delegate determined that the problem sought to be overcome was the efficient use of fixed computing resources when the client has unpredictable demands. The solution lay in the computing resources provider offering a level of service for the customer with what in essence was a ‘payment plan’ or a ‘service level agreement’, where the customer was provided with a guaranteed minimum level of service as well as “burst performance” should they have accumulated sufficient resource credits from previous time periods.

When considering any technical processes involved in the solution provided, the Delegate noted that the invention was not reliant on any optimised algorithm, artificial intelligence or advanced critical path analysis function and found that there was no improvement in computing hardware or architecture.

In contrast, the applicant argued that the problem of “how to” provide the solution was actually a technical problem, and that the solution “brought together a combination of new and known elements to form a working combination that had not previously been achieved, involving the use of computers in a way foreign to their normal use”.

Outcome

The Delegate considered that the problem to be solved by the invention was something that is a “core tenet” of business, namely, avoiding underutilised assets, reinforcing the notion that the problem to be solved was a business problem. He also found that the solution was defined by established business rules.

The Delegate also considered that the applicant’s arguments with regard to the proposed technical effect of the invention would only apply in a very particular and niche situation, and he regarded most other scenarios where the invention might be applied as not achieving a useful result.

The Delegate added that on the rare occasions the useful result was achieved, this was largely dependent on a business decision being made by the customer.

As such the invention related to a business problem rather than a technical problem, and the substance of the invention amounted to “nothing more than a scheme for scheduling work and is therefore not for a manner of manufacture”. In terms of how the work was scheduled, the Delegate stated that there is “no technical innovation in how tasks are scheduled; they are scheduled based on business rules only”.

Implications

This decision is a reminder to patent applicants that it may not be sufficient to merely claim a technical effect achieved by an invention in limited scenarios, and that it is also important to establish that the problem to be solved is a technical one. While there may be cases where an invention is patentable by virtue of a business problem being solved with a technical solution,2 it is preferable that both the problem and solution be technical in nature.

 

  1. [2016] APO 49
  2. See, for example, Advanced New Technologies Co., Ltd [2021] APO 29
Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.   Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.

Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”.  Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News